CR1 in Alzheimer's Disease

Molecular Neurobiology

Volumn 51, Issue 2, 2015, Pages 753-765

  Zhu, Xi Chen ^a   Yu, Jin Tai ^a,b,c   Jiang, Teng ^a   Wang, Ping ^b   Cao, Lei ^a   Tan, Lan ^a,b,c  

^a NANJING MEDICAL UNIVERSITY   (China)

^b QINGDAO UNIVERSITY   (China)

^c OCEAN UNIVERSITY OF CHINA   (China)

Author keywords

Alzheimer's disease; CR1; Genetics; Pathogenesis

Indexed keywords

COMPLEMENT COMPONENT C3B RECEPTOR; CR1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; ANIMAL; CASE CONTROL STUDY; GENETIC PREDISPOSITION; GENETICS; HUMAN; SINGLE NUCLEOTIDE POLYMORPHISM;

ALZHEIMER DISEASE; ANIMALS; CASE-CONTROL STUDIES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, COMPLEMENT 3B;

EID: 84939892984     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-014-8723-8     Document Type: Review

References (91)

1. Jiang T, Yu JT, Tian Y, Tan L (2013) Epidemiology and etiology of Alzheimer's disease: from genetic to non-genetic factors. Curr Alzheimer Res 10(8):852–867
2. Eikelenboom P, Veerhuis R, Scheper W, Rozemuller AJ, van Gool WA, Hoozemans JJ (2006) The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 113(11):1685–1695. doi:10.1007/s00702-006-0575-6
3. Jiang T, Yu JT, Tan L (2012) Novel disease-modifying therapies for Alzheimer's disease. J Alzheim Dis JAD 31(3):475–492. doi:10.3233/JAD-2012-120640
4. Rogaeva E, Kawarai T, George-Hyslop PS (2006) Genetic complexity of Alzheimer's disease: successes and challenges. J Alzheim Dis JAD 9(3 Suppl):381–387
5. Carrasquillo MM, Belbin O, Hunter TA, Ma L, Bisceglio GD, Zou F, Crook JE, Pankratz VS, Dickson DW, Graff-Radford NR, Petersen RC, Morgan K, Younkin SG (2010) Replication of CLU, CR1, and PICALM associations with alzheimer disease. Arch Neurol 67(8):961–964. doi:10.1001/archneurol.2010.147
6. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, Heun R, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, Williams J (2009) Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41(10):1088–1093. doi:10.1038/ng.440
7. Hollingworth P, Harold D, Sims R, Gerrish A, Lambert JC, Carrasquillo MM, Abraham R, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Jones N, Stretton A, Thomas C, Richards A, Ivanov D, Widdowson C, Chapman J, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Beaumont H, Warden D, Wilcock G, Love S, Kehoe PG, Hooper NM, Vardy ER, Hardy J, Mead S, Fox NC, Rossor M, Collinge J, Maier W, Jessen F, Ruther E, Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Gallacher J, Hull M, Rujescu D, Giegling I, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, systemic lupus erythematosusegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Pankratz VS, Sando SB, Aasly JO, Barcikowska M, Wszolek ZK, Dickson DW, Graff-Radford NR, Petersen RC, van Duijn CM, Breteler MM, Ikram MA, DeStefano AL, Fitzpatrick AL, Lopez O, Launer LJ, Seshadri S, Berr C, Campion D, Epelbaum J, Dartigues JF, Tzourio C, Alperovitch A, Lathrop M, Feulner TM, Friedrich P, Riehle C, Krawczak M, Schreiber S, Mayhaus M, Nicolhaus S, Wagenpfeil S, Steinberg S, Stefansson H, Stefansson K, Snaedal J, Bjornsson S, Jonsson PV, Chouraki V, Genier-Boley B, Hiltunen M, Soininen H, Combarros O, Zelenika D, Delepine M, Bullido MJ, Pasquier F, Mateo I, Frank-Garcia A, Porcellini E, Hanon O, Coto E, Alvarez V, Bosco P, Siciliano G, Mancuso M, Panza F, Solfrizzi V, Nacmias B, Sorbi S, Bossu P, Piccardi P, Arosio B, Annoni G, Seripa D, Pilotto A, Scarpini E, Galimberti D, Brice A, Hannequin D, Licastro F, Jones L, Holmans PA, Jonsson T, Riemenschneider M, Morgan K, Younkin SG, Owen MJ, O'Donovan M, Amouyel P, Williams J (2011) Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer’s disease. Nat Genet 43(5):429–435. doi:10.1038/ng.803
8. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, Amouyel P (2009) Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41(10):1094–1099. doi:10.1038/ng.439
9. Naj AC, Jun G, Beecham GW, Wang LS, Vardarajan BN, Buros J, Gallins PJ, Buxbaum JD, Jarvik GP, Crane PK, Larson EB, Bird TD, Boeve BF, Graff-Radford NR, De Jager PL, Evans D, Schneider JA, Carrasquillo MM, Ertekin-Taner N, Younkin SG, Cruchaga C, Kauwe JS, Nowotny P, Kramer P, Hardy J, Huentelman MJ, Myers AJ, Barmada MM, Demirci FY, Baldwin CT, Green RC, Rogaeva E, St George-Hyslop P, Arnold SE, Barber R, Beach T, Bigio EH, Bowen JD, Boxer A, Burke JR, Cairns NJ, Carlson CS, Carney RM, Carroll SL, Chui HC, Clark DG, Corneveaux J, Cotman CW, Cummings JL, DeCarli C, DeKosky ST, Diaz-Arrastia R, Dick M, Dickson DW, Ellis WG, Faber KM, Fallon KB, Farlow MR, Ferris S, Frosch MP, Galasko DR, Ganguli M, Gearing M, Geschwind DH, Ghetti B, Gilbert JR, Gilman S, Giordani B, Glass JD, Growdon JH, Hamilton RL, Harrell LE, Head E, Honig LS, Hulette CM, Hyman BT, Jicha GA, Jin LW, Johnson N, Karlawish J, Karydas A, Kaye JA, Kim R, Koo EH, Kowall NW, Lah JJ, Levey AI, Lieberman AP, Lopez OL, Mack WJ, Marson DC, Martiniuk F, Mash DC, Masliah E, McCormick WC, McCurry SM, McDavid AN, McKee AC, Mesulam M, Miller BL, Miller CA, Miller JW, Parisi JE, Perl DP, Peskind E, Petersen RC, Poon WW, Quinn JF, Rajbhandary RA, Raskind M, Reisberg B, Ringman JM, Roberson ED, Rosenberg RN, Sano M, Schneider LS, Seeley W, Shelanski ML, Slifer MA, Smith CD, Sonnen JA, Spina S, Stern RA, Tanzi RE, Trojanowski JQ, Troncoso JC, Van Deerlin VM, Vinters HV, Vonsattel JP, Weintraub S, Welsh-Bohmer KA, Williamson J, Woltjer RL, Cantwell LB, Dombroski BA, Beekly D, Lunetta KL, Martin ER, Kamboh MI, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Montine TJ, Goate AM, Blacker D, Tsuang DW, Hakonarson H, Kukull WA, Foroud TM, Haines JL, Mayeux R, Pericak-Vance MA, Farrer LA, Schellenberg GD (2011) Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. Nat Genet 43(5):436–441. doi:10.1038/ng.801
10. Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ (2013) The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception. Alzheimers Dement J Alzheimers Assoc 9(5):e111–e194. doi:10.1016/j.jalz.2013.05.1769
11. Bertram L, McQueen MB, Mullin K, Blacker D, Tanzi RE (2007) Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat Genet 39(1):17–23. doi:10.1038/ng1934
12. Brouwers N, Van Cauwenberghe C, Engelborghs S, Lambert JC, Bettens K, Le Bastard N, Pasquier F, Montoya AG, Peeters K, Mattheijssens M, Vandenberghe R, Deyn PP, Cruts M, Amouyel P, systemic lupus erythematosusegers K, Van Broeckhoven C (2012) Alzheimer risk associated with a copy number variation in the complement receptor 1 increasing C3b/C4b binding sites. Mol Psychiatry 17(2):223–233. doi:10.1038/mp.2011.24
13. Biffi A, Shulman JM, Jagiella JM, Cortellini L, Ayres AM, Schwab K, Brown DL, Silliman SL, Selim M, Worrall BB, Meschia JF, Slowik A, De Jager PL, Greenberg SM, Schneider JA, Bennett DA, Rosand J (2012) Genetic variation at CR1 increases risk of cerebral amyloid angiopathy. Neurology 78(5):334–341. doi:10.1212/WNL.0b013e3182452b40
14. Gandy S, Haroutunian V, DeKosky ST, Sano M, Schadt EE (2013) CR1 and the “vanishing amyloid” hypothesis of Alzheimer's disease. Biol Psychiatry 73(5):393–395. doi:10.1016/j.biopsych.2013.01.013
15. Khera R, Das N (2009) Complement Receptor 1: disease associations and therapeutic implications. Mol Immunol 46(5):761–772. doi:10.1016/j.molimm.2008.09.026
16. Weis JH, Morton CC, Bruns GA, Weis JJ, Klickstein LB, Wong WW, Fearon DT (1987) A complement receptor locus: genes encoding C3b/C4b receptor and C3d/Epstein-Barr virus receptor map to 1q32. J Immunol 138(1):312–315
17. Holers VM, Chaplin DD, Leykam JF, Gruner BA, Kumar V, Atkinson JP (1987) Human complement C3b/C4b receptor (CR1) mRNA polymorphism that correlates with the CR1 allelic molecular weight polymorphism. Proc Natl Acad Sci U S A 84(8):2459–2463
18. Wong WW (1990) Structural and functional correlation of the human complement receptor type 1. J Investig Dermatol 94(6 Suppl):64S–67S
19. Moulds JM, Reveille JD, Arnett FC (1996) Structural polymorphisms of complement receptor 1 (CR1) in systemic lupus erythematosus (systemic lupus erythematosus) patients and normal controls of three ethnic groups. Clin Exp Immunol 105(2):302–305
20. Katyal M, Sivasankar B, Ayub S, Das N (2003) Genetic and structural polymorphism of complement receptor 1 in normal Indian subjects. Immunol Lett 89(2–3):93–98
21. Noumsi GT, Tounkara A, Diallo H, Billing systemic lupus erythematosusy K, Moulds JJ, Moulds JM (2011) Knops blood group polymorphism and susceptibility to Mycobacterium tuberculosis infection. Transfusion 51(11):2462–2469. doi:10.1111/j.1537-2995.2011.03161.x
22. Klickstein LB, Wong WW, Smith JA, Weis JH, Wilson JG, Fearon DT (1987) Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med 165(4):1095–1112
23. Klickstein LB, Bartow TJ, Miletic V, Rabson LD, Smith JA, Fearon DT (1988) Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med 168(5):1699–1717
24. Liu D, Niu ZX (2009) The structure, genetic polymorphisms, expression and biological functions of complement receptor type 1 (CR1/CD35). Immunopharmacol Immunotoxicol 31(4):524–535. doi:10.3109/08923970902845768
25. Krych-Goldberg M, Atkinson JP (2001) Structure-function relationships of complement receptor type 1. Immunol Rev 180:112–122
26. Krych-Goldberg M, Hauhart RE, Subramanian VB, Yurcisin BM 2nd, Crimmins DL, Hourcade DE, Atkinson JP (1999) Decay accelerating activity of complement receptor type 1 (CD35). Two active sites are required for dissociating C5 convertases. J Biol Chem 274(44):31160–31168
27. Krych M, Clemenza L, Howdeshell D, Hauhart R, Hourcade D, Atkinson JP (1994) Analysis of the functional domains of complement receptor type 1 (C3b/C4b receptor; CD35) by substitution mutagenesis. J Biol Chem 269(18):13273–13278
28. Krych M, Hauhart R, Atkinson JP (1998) Structure-function analysis of the active sites of complement receptor type 1. J Biol Chem 273(15):8623–8629
29. Tas SW, Klickstein LB, Barbashov SF, Nicholson-Weller A (1999) C1q and C4b bind simultaneously to CR1 and additively support erythrocyte adhesion. J Immunol 163(9):5056–5063
30. Kolev MV, Ruseva MM, Harris CL, Morgan BP, Donev RM (2009) Implication of complement system and its regulators in Alzheimer's disease. Curr Neuropharmacol 7(1):1–8. doi:10.2174/157015909787602805
31. Donev R, Kolev M, Millet B, Thome J (2009) Neuronal death in Alzheimer's disease and therapeutic opportunities. J Cell Mol Med 13(11–12):4329–4348. doi:10.1111/j.1582-4934.2009.00889.x
32. Pisalyaput K, Tenner AJ (2008) Complement component C1q inhibits beta-amyloid- and serum amyloid P-induced neurotoxicity via caspase- and calpain-independent mechanisms. J Neurochem 104(3):696–707. doi:10.1111/j.1471-4159.2007.05012.x
33. Heese K, Hock C, Otten U (1998) Inflammatory signals induce neurotrophin expression in human microglial cells. J Neurochem 70(2):699–707
34. van Beek J, Nicole O, Ali C, Ischenko A, MacKenzie ET, Buisson A, Fontaine M (2001) Complement anaphylatoxin C3a is selectively protective against NMDA-induced neuronal cell death. Neuroreport 12(2):289–293
35. Loeffler DA, Camp DM, Bennett DA (2008) Plaque complement activation and cognitive loss in Alzheimer's disease. J Neuroinflammation 5:9. doi:10.1186/1742-2094-5-9
36. Bonifati DM, Kishore U (2007) Role of complement in neurodegeneration and neuroinflammation. Mol Immunol 44(5):999–1010. doi:10.1016/j.molimm.2006.03.007
37. Birmingham DJ, Chen W, Liang G, Schmitt HC, Gavit K, Nagaraja HN (2003) A CR1 polymorphism associated with constitutive erythrocyte CR1 levels affects binding to C4b but not C3b. Immunology 108(4):531–538
38. Erdei A, Isaak A, Torok K, Sandor N, Kremlitzka M, Prechl J, Bajtay Z (2009) Expression and role of CR1 and CR2 on B and T lymphocytes under physiological and autoimmune conditions. Mol Immunol 46(14):2767–2773. doi:10.1016/j.molimm.2009.05.181
39. Vedeler CA, Matre R (1990) Peripheral nerve CR1 express in situ cofactor activity for degradation of C3b. J Neuroimmunol 26(1):51–56
40. Corneveaux JJ, Myers AJ, Allen AN, Pruzin JJ, Ramirez M, Engel A, Nalls MA, Chen K, Lee W, Chewning K, Villa SE, Meechoovet HB, Gerber JD, Frost D, Benson HL, O'Reilly S, Chibnik LB, Shulman JM, Singleton AB, Craig DW, Van Keuren-Jensen KR, Dunckley T, Bennett DA, De Jager PL, Heward C, Hardy J, Reiman EM, Huentelman MJ (2010) Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Hum Mol Genet 19(16):3295–3301. doi:10.1093/hmg/ddq221
41. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P, Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, Schellenberg GD (2010) Meta-analysis confirms CR1, CLU, and PICALM as alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 67(12):1473–1484. doi:10.1001/archneurol.2010.201
42. Zhang Q, Yu JT, Zhu QX, Zhang W, Wu ZC, Miao D, Tan L (2010) Complement receptor 1 polymorphisms and risk of late-onset Alzheimer's disease. Brain Res 1348:216–221. doi:10.1016/j.brainres.2010.06.018
43. Wijsman EM, Pankratz ND, Choi Y, Rothstein JH, Faber KM, Cheng R, Lee JH, Bird TD, Bennett DA, Diaz-Arrastia R, Goate AM, Farlow M, Ghetti B, Sweet RA, Foroud TM, Mayeux R (2011) Genome-wide association of familial late-onset Alzheimer's disease replicates BIN1 and CLU and nominates CUGBP2 in interaction with APOE. PLoS Genet 7(2):e1001308. doi:10.1371/journal.pgen.1001308
44. Schjeide BM, Schnack C, Lambert JC, Lill CM, Kirchheiner J, Tumani H, Otto M, Tanzi RE, Lehrach H, Amouyel P, von Arnim CA, Bertram L (2011) The role of clusterin, complement receptor 1, and phosphatidylinositol binding clathrin assembly protein in Alzheimer disease risk and cerebrospinal fluid biomarker levels. Arch Gen Psychiatry 68(2):207–213. doi:10.1001/archgenpsychiatry.2010.196
45. Chen LH, Kao PY, Fan YH, Ho DT, Chan CS, Yik PY, Ha JC, Chu LW, Song YQ (2012) Polymorphisms of CR1, CLU and PICALM confer susceptibility of Alzheimer's disease in a southern Chinese population. Neurobiol Aging 33(1):210 e211–217. doi:10.1016/j.neurobiolaging.2011.09.016
46. Jin C, Li W, Yuan J, Xu W, Cheng Z (2012) Association of the CR1 polymorphism with late-onset Alzheimer's disease in Chinese Han populations: a meta-analysis. Neurosci Lett 527(1):46–49. doi:10.1016/j.neulet.2012.08.032
47. Hazrati LN, Van Cauwenberghe C, Brooks PL, Brouwers N, Ghani M, Sato C, Cruts M, systemic lupus erythematosusegers K, St George-Hyslop P, Van Broeckhoven C, Rogaeva E (2012) Genetic association of CR1 with Alzheimer's disease: a tentative disease mechanism. Neurobiol Aging 33(12):2949 e2945–2949 e2912. doi:10.1016/j.neurobiolaging.2012.07.001
48. Ma XY, Yu JT, Tan MS, Sun FR, Miao D, Tan L (2014) Missense variants in CR1 are associated with increased risk of Alzheimer' disease in Han Chinese. Neurobiol Aging 35(2):443 e417–421. doi:10.1016/j.neurobiolaging.2013.08.009
49. Chung SJ, Kim MJ, Kim YJ, Kim J, You S, Jang EH, Kim SY, Lee JH (2014) CR1, ABCA7, and APOE genes affect the features of cognitive impairment in Alzheimer's disease. J Neurol Sci. doi:10.1016/j.jns.2014.01.029
50. Kim CH, Kim HS, Cubells JF, Kim KS (1999) A previously undescribed intron and extensive 5' upstream sequence, but not Phox2a-mediated transactivation, are necessary for high level cell type-specific expression of the human norepinephrine transporter gene. J Biol Chem 274(10):6507–6518
51. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease (2013). Nature genetics 45 (12):1452-1458. doi:10.1038/ng.2802
52. Chung SJ, Lee JH, Kim SY, You S, Kim MJ, Lee JY, Koh J (2013) Association of GWAS top hits with late-onset Alzheimer disease in Korean population. Alzheimer Dis Assoc Disord 27(3):250–257. doi:10.1097/WAD.0b013e31826d7281
53. Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, Schneider JA (2011) Cerebral amyloid angiopathy pathology and cognitive domains in older persons. Ann Neurol 69(2):320–327. doi:10.1002/ana.22112
54. Thambisetty M, An Y, Nalls M, Sojkova J, Swaminathan S, Zhou Y, Singleton AB, Wong DF, Ferrucci L, Saykin AJ, Resnick SM (2013) Effect of complement CR1 on brain amyloid burden during aging and its modification by APOE genotype. Biol Psychiatry 73(5):422–428. doi:10.1016/j.biopsych.2012.08.015
55. Kok EH, Luoto T, Haikonen S, Goebeler S, Haapasalo H, Karhunen PJ (2011) CLU, CR1 and PICALM genes associate with Alzheimer's-related senile plaques. Alzheimers Res Ther 3(2):12. doi:10.1186/alzrt71
56. Biffi A, Anderson CD, Desikan RS, Sabuncu M, Cortellini L, Schmansky N, Salat D, Rosand J (2010) Genetic variation and neuroimaging measures in Alzheimer disease. Arch Neurol 67(6):677–685. doi:10.1001/archneurol.2010.108
57. Furney SJ, Simmons A, Breen G, Pedroso I, Lunnon K, Proitsi P, Hodges A, Powell J, Wahlund LO, Kloszewska I, Mecocci P, Soininen H, Tsolaki M, Vellas B, Spenger C, Lathrop M, Shen L, Kim S, Saykin AJ, Weiner MW, Lovestone S (2011) Genome-wide association with MRI atrophy measures as a quantitative trait locus for Alzheimer's disease. Mol Psychiatry 16(11):1130–1138. doi:10.1038/mp.2010.123
58. Keenan BT, Shulman JM, Chibnik LB, Raj T, Tran D, Sabuncu MR, Allen AN, Corneveaux JJ, Hardy JA, Huentelman MJ, Lemere CA, Myers AJ, Nicholson-Weller A, Reiman EM, Evans DA, Bennett DA, De Jager PL (2012) A coding variant in CR1 interacts with APOE-epsilon4 to influence cognitive decline. Hum Mol Genet 21(10):2377–2388. doi:10.1093/hmg/dds054
59. Mengel-From J, Christensen K, McGue M, Christiansen L (2011) Genetic variations in the CLU and PICALM genes are associated with cognitive function in the oldest old. Neurobiol Aging 32(3):554 e557–511. doi:10.1016/j.neurobiolaging.2010.07.016
60. Chibnik LB, Shulman JM, Leurgans SE, Schneider JA, Wilson RS, Tran D, Aubin C, Buchman AS, Heward CB, Myers AJ, Hardy JA, Huentelman MJ, Corneveaux JJ, Reiman EM, Evans DA, Bennett DA, De Jager PL (2011) CR1 is associated with amyloid plaque burden and age-related cognitive decline. Ann Neurol 69(3):560–569. doi:10.1002/ana.22277
61. Pedraza O, Allen M, Jennette K, Carrasquillo M, Crook J, Serie D, Pankratz VS, Palusak R, Nguyen T, Malphrus K, Ma L, Bisceglio G, Roberts RO, Lucas JA, Ivnik RJ, Smith GE, Graff-Radford NR, Petersen RC, Younkin SG, Ertekin-Taner N (2013) Evaluation of memory endophenotypes for association with CLU, CR1, and PICALM variants in black and white subjects. Alzheimers Dement J Alzheimers Assoc. doi:10.1016/j.jalz.2013.01.016
62. Bralten J, Franke B, Arias-Vasquez A, Heister A, Brunner HG, Fernandez G, Rijpkema M (2011) CR1 genotype is associated with entorhinal cortex volume in young healthy adults. Neurobiol Aging 32(11):2106 e2107–2111. doi:10.1016/j.neurobiolaging.2011.05.017
63. Mawuenyega KG, Sigurdson W, Ovod V, Munsell L, Kasten T, Morris JC, Yarasheski KE, Bateman RJ (2010) Decreased clearance of CNS beta-amyloid in Alzheimer's disease. Science 330(6012):1774. doi:10.1126/science.1197623
64. Joachim CL, Mori H, Selkoe DJ (1989) Amyloid beta-protein deposition in tissues other than brain in Alzheimer's disease. Nature 341(6239):226–230. doi:10.1038/341226a0
65. Li QX, Whyte S, Tanner JE, Evin G, Beyreuther K, Masters CL (1998) Secretion of Alzheimer's disease Abeta amyloid peptide by activated human platelets. Lab Investig J Tech Methods Pathol 78(4):461–469
66. Mayeux R, Tang MX, Jacobs DM, Manly J, Bell K, Merchant C, Small SA, Stern Y, Wisniewski HM, Mehta PD (1999) Plasma amyloid beta-peptide 1-42 and incipient Alzheimer's disease. Ann Neurol 46(3):412–416
67. Scheuner D, Eckman C, Jensen M, Song X, Citron M, Suzuki N, Bird TD, Hardy J, Hutton M, Kukull W, Larson E, Levy-Lahad E, Viitanen M, Peskind E, Poorkaj P, Schellenberg G, Tanzi R, Wasco W, Lannfelt L, Selkoe D, Younkin S (1996) Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nat Med 2(8):864–870
68. Matsubara E, Ghiso J, Frangione B, Amari M, Tomidokoro Y, Ikeda Y, Harigaya Y, Okamoto K, Shoji M (1999) Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome. Ann Neurol 45(4):537–541
69. Kuo YM, Kokjohn TA, Kalback W, Luehrs D, Galasko DR, Chevallier N, Koo EH, Emmerling MR, Roher AE (2000) Amyloid-beta peptides interact with plasma proteins and erythrocytes: implications for their quantitation in plasma. Biochem Biophys Res Commun 268(3):750–756. doi:10.1006/bbrc.2000.2222
70. Rogers J, Cooper NR, Webster S, Schultz J, McGeer PL, Styren SD, Civin WH, Brachova L, Bradt B, Ward P et al (1992) Complement activation by beta-amyloid in Alzheimer disease. Proc Natl Acad Sci U S A 89(21):10016–10020
71. Rogers J, Li R, Mastroeni D, Grover A, Leonard B, Ahern G, Cao P, Kolody H, Vedders L, Kolb WP, Sabbagh M (2006) Peripheral clearance of amyloid beta peptide by complement C3-dependent adherence to erythrocytes. Neurobiol Aging 27(12):1733–1739. doi:10.1016/j.neurobiolaging.2005.09.043
72. Ghiso J, Shayo M, Calero M, Ng D, Tomidokoro Y, Gandy S, Rostagno A, Frangione B (2004) Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem 279(44):45897–45908. doi:10.1074/jbc.M407668200
73. DeMattos RB, Bales KR, Cummins DJ, Dodart JC, Paul SM, Holtzman DM (2001) Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease. Proc Natl Acad Sci U S A 98(15):8850–8855. doi:10.1073/pnas.151261398
74. Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T (2000) Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med 6(8):916–919. doi:10.1038/78682
75. Li J, Wang JP, Ghiran I, Cerny A, Szalai AJ, Briles DE, Finberg RW (2010) Complement receptor 1 expression on mouse erythrocytes mediates clearance of Streptococcus pneumoniae by immune adherence. Infect Immun 78(7):3129–3135. doi:10.1128/IAI.01263-09
76. Crehan H, Hardy J, Pocock J (2013) Blockage of CR1 prevents activation of rodent microglia. Neurobiol Dis 54:139–149. doi:10.1016/j.nbd.2013.02.003
77. Fetler L, Amigorena S (2005) Neuroscience. Brain under surveillance: the microglia patrol. Science 309(5733):392–393. doi:10.1126/science.1114852
78. Lautner R, Mattsson N, Scholl M, Augutis K, Blennow K, Olsson B, Zetterberg H (2011) Biomarkers for microglial activation in Alzheimer's disease. Int J Alzheimers Dis 2011:939426. doi:10.4061/2011/939426
79. Jones L, Holmans PA, Hamshere ML, Harold D, Moskvina V, Ivanov D, Pocklington A, Abraham R, Hollingworth P, Sims R, Gerrish A, Pahwa JS, Jones N, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, Heun R, Kolsch H, van den Bussche H, Heuser I, Peters O, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Ruther E, Carrasquillo MM, Pankratz VS, Younkin SG, Hardy J, O'Donovan MC, Owen MJ, Williams J (2010) Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS ONE 5(11):e13950. doi:10.1371/journal.pone.0013950
80. Tohyama Y, Yamamura H (2006) Complement-mediated phagocytosis—the role of Syk. IUBMB Life 58(5–6):304–308. doi:10.1080/15216540600746377
81. Systemic lupus erythematosusegers K, Lambert JC, Bertram L, Cruts M, Amouyel P, Van Broeckhoven C (2010) The pursuit of susceptibility genes for Alzheimer's disease: progress and prospects. Trends Genet TIG 26(2):84–93. doi:10.1016/j.tig.2009.12.004
82. Song WC, Sarrias MR, Lambris JD (2000) Complement and innate immunity. Immunopharmacology 49(1–2):187–198
83. Akiyama H, Barger S, Barnum S, Bradt B, Bauer J, Cole GM, Cooper NR, Eikelenboom P, Emmerling M, Fiebich BL, Finch CE, Frautschy S, Griffin WS, Hampel H, Hull M, Landreth G, Lue L, Mrak R, Mackenzie IR, McGeer PL, O'Banion MK, Pachter J, Pasinetti G, Plata-Salaman C, Rogers J, Rydel R, Shen Y, Streit W, Strohmeyer R, Tooyoma I, Van Muiswinkel FL, Veerhuis R, Walker D, Webster S, Wegrzyniak B, Wenk G, Wyss-Coray T (2000) Inflammation and Alzheimer's disease. Neurobiol Aging 21(3):383–421
84. Wyss-Coray T, Yan F, Lin AH, Lambris JD, Alexander JJ, Quigg RJ, Masliah E (2002) Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc Natl Acad Sci U S A 99(16):10837–10842. doi:10.1073/pnas.162350199
85. Killick R, Hughes TR, Morgan BP, Lovestone S (2013) Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH. Neurosci Lett 533:96–99. doi:10.1016/j.neulet.2012.11.008
86. Yoon SH, Fearon DT (1985) Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J Immunol 134(5):3332–3338
87. Pascual M, Duchosal MA, Steiger G, Giostra E, Pechere A, Paccaud JP, Danielsson C, Schifferli JA (1993) Circulating soluble CR1 (CD35). Serum levels in diseases and evidence for its release by human leukocytes. J Immunol 151(3):1702–1711
88. Hamer I, Paccaud JP, Belin D, Maeder C, Carpentier JL (1998) Soluble form of complement C3b/C4b receptor (CR1) results from a proteolytic cleavage in the C-terminal region of CR1 transmembrane domain. The Biochemical journal 329(Pt 1):183–190
89. Ramaglia V, Wolterman R, de Kok M, Vigar MA, Wagenaar-Bos I, King RH, Morgan BP, Baas F (2008) Soluble complement receptor 1 protects the peripheral nerve from early axon loss after injury. Am J Pathol 172(4):1043–1052. doi:10.2353/ajpath.2008.070660
90. Jacquet M, Lacroix M, Ancelet S, Gout E, Gaboriaud C, Thielens NM, Rossi V (2013) Deciphering complement receptor type 1 interactions with recognition proteins of the lectin complement pathway. J Immunol 190(7):3721–3731. doi:10.4049/jimmunol.1202451
91. Kubiak-Wlekly A, Perkowska-Ptasinska A, Olejniczak P, Rochowiak A, Kaczmarek E, Durlik M, Czekalski S, Niemir ZI (2009) The comparison of the podocyte expression of synaptopodin, CR1 and neprilysin in human glomerulonephritis: could the expression of CR1 be clinically relevant? Int J Biomed Sci IJBS 5(1):28–36